Eugit Therapeutics is thrilled to announce that we have been awarded an NSF Phase 1 grant for our work on tissue targeting technology. This milestone wouldn't have been possible without the incredible support and collaboration of many individuals and organizations: - George Church, Nizar Batada, Yoshinori Fukazawa, Ernest F. Ribera, M.D. NAMITA ROUT -- thank you for your relentless dedication. - Our investors, including Y Combinator, Ethan Perlstein and Oleksiy Ignatyev, Ph.D. who believed in our vision. - To our friends, colleagues and mentors—Prof. Dietmar Zaiss, Stefan Symeonides, Mark Selby, Joe Collura, Douglas Crawford Lexi Rovner and many others -- your guidance has been invaluable. - A special thanks to the NSF and our Program Officer, Henry Ahn and the grant reviewers, for believing in our potential. - And last but not least, Ana Ortiz, PhD, for your exceptional support with the grant writeup.
关于我们
Cofounded by George Church (Harvard) and funded by Y Combinator (S22) and NSF Ph1 grant (https://www.nsf.gov/awardsearch/showAward?AWD_ID=2423571&HistoricalAwards=false)
- 网站
-
Www.eugittx.com
Eugit Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- San Carlos，California
- 类型
- 私人持股
- 创立
- 2022
- 领域
- Immune system、Drug discovery、Immune-mediated diseases、Inflammatory Bowels Disease、IBD和gamma delta T cells
地点
-
主要
获取路线
US，California ，San Carlos